Why Is Clovis Oncology Stock Trading Higher Today?


Clovis Oncology Inc CLVS shares are trading higher Monday after the company presented data showing Rubraca as a first-line maintenance treatment improved progression-free survival in advanced ovarian cancer.

Clovis announced results from a subgroup analysis of data from the monotherapy comparison of the randomized, Phase 3 ATHENA trial over the weekend. Rubraca as first-line maintenance treatment improved progression-free survival versus placebo across disease risk subgroups including surgical outcome, response to first-line chemotherapy and additional analyses in other subgroups. 

"As further demonstrated by the additional data presented at ESMO, the ATHENO-MONO analysis continues to reinforce the potential of Rubraca as a first-line maintenance therapy for women with advanced ovarian cancer," said Patrick Mahaffy, president and CEO of Clovis Oncology. 

Clovis is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the US, Europe and additional international markets. 

See Also: Why InMed Pharmaceuticals Stock Is Rising Today

CLVS Price Action: Clovis has a 52-week high of $3.25 and a 52-week low of 58 cents.

The stock was up 13.9% at $1.30 at time of publication, according to Benzinga Pro.

Photo: Tatiana from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: Penny StocksMoversTrading Ideaspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!